导 师 个 人 简 介

个人简介

林治华，二级教授，博士生导师。教育部新世纪优秀人才，重庆市有突出贡献的中青年专家，重庆市首批科技创新领军人才，重庆市免疫学会副理事长。1988.09-1992.07获成都科技大学（现四川大学）无机化工专业学士学位，1997.09-2000.07获重庆大学物理化学专业硕士学位，2000.09-2003.07获中国人民解放军第三军医大学（现陆军军医大学）免疫学专业医学博士学位。2002.01-至今 重庆理工大学药学与生物工程学院教师。在国内外重要学术刊物发表研究论文100余篇，其中SCI收录70余篇；授权发明专利10件；编写著作或教材3部。获得2008年度高等学校科学研究优秀成果奖（自然科学奖）二等奖1项（排名第一），2008年度重庆市科技进步二等奖1项（排名第四），2009年度中华医学科技奖一等奖1项（排名第八），2016年中华医学科技奖三等奖1项（排名第三）。

研究领域

药物设计与合成

承担的主要项目

[1] HPV16型E7抗原CTL表位模拟肽抗HPV感染的实验研究，国家自然科学基金面上项目，2012.01-2015.12，58万元，主持。

[2] 基于CTL免疫识别的结构信息表达及构效关系建模，国家自然科学基金面上项目，2009.01-2011.12，30万元，主持。

[3] 高效树突状细胞靶向DNA疫苗激发抗宫颈癌免疫应答的实验研究，国家自然科学基金面上项目，2007.01-2009.12，27万元，主持。

[4] 基于非蛋白氨基酸设计合成CTL模拟表位及免疫学效应的研究，国家自然科学基金面上项目2006.01-2008.12，24万，主持。

[5] 一种具有抗HBV活性的抗艾药物抗HBV作用机制的研究，重庆市自然科学基金重点项目，2016.4-2019.3，20万，主持。

[6] 介导金黄色葡萄球菌免疫逃逸的目标分子及作用机制，重庆市自然科学基金重点项目，2012.08-2015.01，20万元，主持。

[7]抗艾药物替拉那韦抗肝癌作用及相关机制研究，重庆市教委重点项目，2018.10-2020.10，20万，主持。

代表性成果

论文

[1]He, QX; Chen, X ; Yang, X ; Li, GP; Gu, HQ ; Chu, H ; Lin, ZH ; Wang, YQ.Virtual Screening of Chinese Medicine Small Molecule Compounds Targeting SARS-CoV-2 3CL Protease (3CL pro).LETTERS IN DRUG DESIGN & DISCOVERY,2021,18: 355-364.

[2]He, QX; Han, C; Li, GP; Guo, HQ; Wang, YX; Hu, Y; Lin, ZH; Wang, YQ.In silico design novel (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine derivatives as inhibitors for glycogen synthase kinase 3 based on 3D-QSAR, molecular docking and molecular dynamics simulation.COMPUTATIONAL BIOLOGY AND CHEMISTRY.2020,88:107328.

[3]He, QX; Chu, H; Wang, YX; Guo, HQ; Wang, YQ; Wang, SY; Feng, ZW; Xie, XQ; Hu, Y; Liu, HB; Lin, ZH.In silico design novel vibsanin B derivatives as inhibitor for heat shock protein 90 based on 3D-QSAR, molecular docking and molecular dynamics simulation.JOURNALOFBIOMOLECULAR STRUCTURE & DYNAMICS. 2019, 38: 4313-4324.

[4]Wang, R; Chen, Y; Shu, M; Zhao, WW; Tao, ML; Du, C; Fu, XY; Li, A; Lin, ZH.AuCl3-Catalyzed Ring-Closing Carbonyl-Olefin Metathesis.CHEMISTRY-A EUROPEAN JOURNAL. 2020, 26: 1941-1946.

[5]Wang, YQ; Guo, HQ; Feng, ZW; Wang, SY; Wang, YX; He, QX; Li, GP; Lin, WW; Xie, XQ; Lin, ZH.PD-1-Targeted Discovery of Peptide Inhibitors by Virtual Screening, Molecular Dynamics Simulation, and Surface Plasmon Resonance.MOLECULES.Accepted. 2019.

[6]Wang, YQ; Lin, WW; Wu, N; Wang, SY; Chen, MZ; Lin, ZH; Xie, XQ; Feng, ZW.Structural insight into the serotonin (5-HT) receptor family by molecular docking, molecular dynamics simulation and systems pharmacology analysis.ACTA PHARMACOLOGICA SINICA. 2019, 40: 1138-1156.

[7]Shu, M; Wu, T; Wang, BW; Li, J; Xu, CM; Lin, ZH.3D-QSAR and Surflex Docking Studies of a Series of Alkaline Phosphatase Inhibitors.CHINESE JOURNAL OF STRUCTURAL CHEMISTRY. 2 019,38:7-16.

[8]Zhang, BN; Shu, M; Xu, CM; An, CH; Wang, R; Lin, ZH.Virtual Screening, Docking, Synthesis and Bioactivity Evaluation of Thiazolidinediones as Potential PPAR gamma Partial Agonists for Preparation of Antidiabetic Agents.LETTERS IN DRUG DESIGN & DISCOVERY. 2019, 16: 608-617.

[9]Junwei Wang，Yating Deng，Han Chu，Juan Wang，Yong Hu，Zhihua Lin.3D-QSAR, Molecular Docking and New Compound Design of Pyrimidine Derivativesas Src Small Molecule Inhibitors. Medicinal Chemistry Research. Accepted.2019

[10]Yating Deng, Junwei Wang, Han Chu, Juan Wang, Yong Hu, Mao Shu,YongLin Zhihua Lin.3D-QSAR and Docking Studies on Pyrimidine Derivatives as CSF-1R inhibitors, Letter inDrugDesign andDiscovery, Accepted. 2019

[11]Haiqiong Guo, Yuxuan Wang, Qingxiu He, Yuping Zhang, Yong Hu, Yuanqiang Wang*, Zhihua Lin. In silico rational design and virtual screening of antixoidant tripeptides based on 3D-QSAR modeling. Journal of Molecular Structure, 2019, 1193(5): 223-230

[12]Yuxuan Wang#, Haiqiong Guo#, Guanghui Tang#, Qingxiu He, Yuping Zhang, Yong Hu, Yuanqiang Wang*, Zhihua Lin. A selectivity study of benzenesulfonamide derivatives on human carbonic anhydrase II/IX by 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation. Computational Biology and Chemistry. 2019, 80: 234-243

[13]Wang, Yuan-Qiang; Lin, Wei-Wei; Wu, Nan; Wang, Si-Yi; Chen, Mao-Zi; Lin, Zhi-Hua; Xie, Xiang-Qun; Feng, Zhi-Wei.Structural insight into the serotonin (5-HT) receptor family by molecular docking, molecular dynamics simulation and systems pharmacology analysis. Acta pharmacologica Sinica. DOI:10.1038/s41401-019-0217-9

[14]Molecular Docking, QSAR and Molecular Dynamics Simulation on PhosphorusContaining Pyrimidines as CDK9 Inhibitors.CHEMICAL JOURNAL OF CHINESE UNIVERSITIES-CHINESE, 2017, 38(11):2061-2069

[15]Study of 1-H Pyrrolo[3,2-c]pyridine MPS1 Inhibitors by Topomer CoMFA, Virtual screening and Molecular Dynamics Simulation.LATIN AMERICAN JOURNAL OF PHARMACY, 2017, 36(1):86-92

[16]Combined 3D-QSAR, Pharmacophore and Docking Studies on Benzene-sulfonamide Derivatives as Potent 12-Lipoxygenase Inhibitors.LETTERS IN DRUG DESIGN & DISCOVERY, 2017, 14(1):74-82

[17]Discovery of vascular endothelial growth factor receptor tyrosine kinase inhibitors by quantitative structure- activity relationships, molecular dynamics simulation and free energy calculation. Rsc Advances，2016，6(42):35402-35415

[18]Identification of potential CCR5 inhibitors through pharmacophore-based virtual screening, molecular dynamics simulation and binding free energy analysis. Molecular Biosystems，2016，12(1):3396-3406

[19]Hypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural Analyses. PLOS ONE.2016, Jan 19;11(1):e0147048.

[20]Quantitative Prediction of Class I MHC/Epitope Binding Affinity Using QSAR Modeling Derived from Amino Acid Structural Information. Comb Chem High Throughput Screen. 2015, 18(1): 75-82.

[21]Combined pharmacophore modeling, 3D-QSAR, homology modeling and docking studies on CYP11B1 inhibitors. Molecules. 2015 Jan 9;20(1):1014-30.

[22]3D-QSAR Analysis on ATR Protein Kinase Inhibitors Using CoMFA and CoMSIA. Current Computer-Aided Drug Design, 2014, 10（4）, 327-334.

[23]Proteasomal cleavage site prediction of protein antigen using BP neural network based on a new set of amino acid descriptor. Journal of molecular modeling, 2013,19(8):3045-3052.

[24]3D-QSAR Studies of Azacycles CCR5 Antagonists Using CoMFA and Topomer CoMFA. Journal of molecular structure, 2013, 1045(3): 35-41.

[25]Predicting the Activity of Antimicrobial Peptides with Amino Acid Topological Information. Medicinal Chemistry, 2013,9（1）：32-44.

[26]3D-QSAR and docking studies of 3-Pyridine heterocyclic derivatives as potent PI3K/mTOR inhibitors. Journal of Molecular Structure, 2013, 1054: 107-116.

[27]3D-QSAR Studies of Dihydropyrazole and Dihydropyrrole Derivatives as Inhibitors of Human Mitotic Kinesin Eg5 Based on Molecular Docking. Molecules, 2012, 17(2), 2015-2029.

[28]QSAR Modeling and Design of Cationic Antimicrobial Peptides Based on Structural Properties of Amino Acids. Combinatorial Chemistry & High Throughput Screening, 2012, 15(4), 347-353.

[29]Quantitative Prediction of TAP and MHC Class I Binding Peptides using QSAR Modeling based on Amino Acid Structural Information. Current Computer-Aided Drug Design, 2012, 8(1), 50-54.

[30]Molecular Docking and 3D-QSAR Research of Biphenyl Carboxylic Acid MMP-3 Inhibitors. Chinese Journal of Structural Chemistry, 2012, 31(3):443-451.

[31]Predicting the activity of ACE inhibitory peptides with a novel mode of pseudo amino acid composition. Protein & Peptide Letters, 2011,18(12):1233-1243.

[32]QSAR Study on MHC Class I A alleles based on the novel parameters of amino acids. Protein & Peptide Letters, 2011,18(9):956-963.

[33]3D-QSAR Studies on Caspase-mediated Apoptosis Activity of Phenolic analogues，Journal of Molecular Modelling, 2011，17(1)：1-8

[34]QSAR study on angiotensin-converting enzyme inhibitor oligopeptides based on a novel set of sequence information descriptors. Journal of Molecular Modelling, 2011,17(7)：1599-1606.

[35]IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochemical and Biophysical ResearchCommunications，2011，407(2):348-354

专利

[1]一种色原酮取代噻唑烷二酮化合物及其用于治疗糖尿病药物的应用，发明人：王锐,林治华,舒茂,安春红,李傲,胡勇,舒杭,陈乐园,杨涛,张兴，ZL 201610111974.6

[2]一种非蛋白氨基酸抗菌肽及其应用，发明人：舒茂,林治华,路亚阔,于蕊,孟令鑫，ZL 201410674290.8

[3]含N双杂环酰胺类化合物及其作为免疫抑制剂的应用，发明人：林治华,常自超,王锐,安春红,杨文娟,舒茂,王远强，ZL201410639776.8

[4]一类喹唑啉类化合物及其作为免疫抑制剂的应用，发明人：林治华,安春红,王锐,常志超,姚爽,舒茂,王远强,胡勇，ZL201410494140.9

[5]一种非蛋白氨基酸抗菌肽及其应用，发明人：林治华,舒茂,路亚阔,于蕊,孟令鑫，ZL 201310246635.5

[6]4-(环己基)-胺基喹唑啉类化合物的应用，发明人：林治华,马正伟,许雪青,朱波,王锐，ZL 201110026959.9

[7]一组动物源性阳离子抗菌肽及其应用，发明人：王远强,林治华,丁元,蔡家利,韩英子，ZL 201110414617.4

[8]肿瘤抗原TRAG-3模拟表位肽及其应用，发明人：朱波,林治华,王槐亮,龙海霞,程晓明,陈正堂，ZL 200910104554.5

[9]与MHC-Ⅰ类分子结合的鼠Ⅲ型肝炎病毒多肽表位及应用，发明人：朱波,龙海霞,林治华,陈正堂，ZL 200910104132.8

获奖

[1]林治华（3/8），乙型肝炎慢性化机制及其防治研究，中华医学会科技奖三等奖，2017.01.03

[2]林治华（8/12），蛋白质抗原的免疫识别、应答及其调节，中华医学会科技奖一等奖，2009.01.20

[3]林治华（1/6），蛋白质抗原表位结构特性与免疫学效应关系的研究，教育部自然科学二等奖，2008.11.25

[4]林治华（4/9），非小细胞肺癌免疫治疗基础及临床应用研究，重庆市科技进步二等奖，2008.11.19

[5]林治华（1/9），生物医药应用型人才“一体两冀”分类培养模式构建与实践，重庆市教学成果奖，2022.05.15

联系方式

Tel：13452006075；E-mail：zhlin@cqut.edu.cn